VistaGen Therapeutics and Baylor College of Medicine Collaborate on First-Step Study to Test VistaGen’s AV-101 for Potential Anti-Suicidal Effects in Veterans
13 août 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
Veterans from Operation Enduring Freedom, Operation Iraqi Freedom and Operation New Dawn to Participate in Study SOUTH SAN FRANCISCO, Calif. and HOUSTON, Aug. 13, 2018 (GLOBE NEWSWIRE) -- VistaGen...
VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights
26 juin 2018 17h12 HE
|
VistaGen Therapeutics, Inc.
AV-101, VistaGen’s Oral NMDA Receptor Modulator, Granted FDA Fast-Track Designation for Major Depressive Disorder Key AV-101 Patents Issued in U.S., Europe and Asia ELEVATE, AV-101 U.S. Phase 2...
VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101
13 juin 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for...
VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders
11 juin 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
Patent Covers Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a...
VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage
23 mai 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression...
VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101
02 mai 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression...